An Open-label Study of a Gene Therapy Product in Beta-Thalassemia

Status Not yet recruiting

Clinical Trial Summary

This is an interventional study to evaluate the safety and efficacy of autologous Hematopoietic Stem Cells (HSCs) transduced with lentiviral vector encoding functional hemoglobin subunit beta (HBB) gene in patients with transfusion-dependent beta-thalassemia.

Clinical Trial Description

The participant's autologous HSCs will be transduced with the self-inactivating lentiviral vector, carrying the functional HBB gene. Study duration per participant is approximately 27 months including an approximately 30-day screening/baseline period, an approximately 40-day mobilization and product manufacture, an approximately 10-day myeloablative conditioning, 1 treatment day, and an approximately 24-month study observation period. The endpoints will be used to assess the safety and efficacy profiles in patients with transfusion-dependent beta-thalassemia. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06308159
Study type	Interventional
Source	Lantu Biopharma
Contact
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	April 1, 2024
Completion date	April 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00069862` - Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia	Phase 1/Phase 2
Completed	`NCT00733811` - Efficacy Study of the Use of Sequential DFP-DFO Versus DFP	Phase 4
Completed	`NCT05506358` - Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada	N/A
Withdrawn	`NCT04938635` - Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia	Phase 2
Active, not recruiting	`NCT03655678` - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia	Phase 2/Phase 3
Completed	`NCT06239389` - Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.	Phase 2
Recruiting	`NCT05635266` - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT03271541` - A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia	Phase 2
Terminated	`NCT02274233` - Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia	Phase 1
Completed	`NCT01206075` - Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major	N/A
Recruiting	`NCT05567458` - A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.	Phase 2
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Completed	`NCT03961828` - Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus	Phase 4
Recruiting	`NCT06065189` - Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major	Early Phase 1
Recruiting	`NCT04143724` - Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia	Phase 2
Terminated	`NCT03381833` - A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia	Phase 2
Not yet recruiting	`NCT01996683` - Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)	N/A
Completed	`NCT02268409` - ACE-536 Extension Study - Beta Thalassemia	Phase 2
Active, not recruiting	`NCT01016093` - Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients	Phase 2/Phase 3
Completed	`NCT01039636` - Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload	Phase 1